{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:42:39Z","timestamp":1786221759051,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-038051"],"award-info":[{"award-number":["INV-038051"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-046971"],"award-info":[{"award-number":["INV-046971"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1625923"],"award-info":[{"award-number":["1625923"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR024664"],"award-info":[{"award-number":["S10RR024664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD036339-01"],"award-info":[{"award-number":["1S10OD036339-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xphs.2026.104199","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:41:54Z","timestamp":1770828114000},"page":"104199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles"],"prefix":"10.1016","volume":"115","author":[{"given":"Max","family":"Fairlamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan S.","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Bevernaegie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien Vander","family":"Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Neuenswander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104199_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA Vaccines in the COVID-19 Pandemic and Beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0002","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: Platforms and current developments","volume":"30","author":"Szabo","year":"2022","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2026.104199_bib0003","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(24)00179-6","article-title":"Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study","volume":"12","author":"Mesle","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.xphs.2026.104199_bib0004","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases - advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"10.1016\/j.xphs.2026.104199_bib0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.xphs.2026.104199_bib0007","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1039\/D4NR00019F","article-title":"Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines","volume":"16","author":"Wu","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.xphs.2026.104199_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115419","article-title":"Advances in the design and delivery of RNA vaccines for infectious diseases","volume":"213","author":"Lokras","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2026.104199_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl Res"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.vaccine.2023.12.031","article-title":"How manufacturing won or lost the COVID-19 vaccine race","volume":"42","author":"King","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/vaccines13020112","article-title":"Investment Opportunities for mRNA Technology in Low- and Middle-Income Countries: Key Findings and Future Perspectives","volume":"13","author":"AdJLd","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0012","first-page":"45","article-title":"Optimization of therapeutic antibodies","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"issue":"3","key":"10.1016\/j.xphs.2026.104199_bib0013","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.xphs.2020.11.039","article-title":"Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens","volume":"110","author":"Sawant","year":"2021","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0014","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat Commun"},{"issue":"7978","key":"10.1016\/j.xphs.2026.104199_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2026.104199_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2023.08.002","article-title":"Evaluating how cationic lipid affects mRNA-LNP physical properties and biodistribution","volume":"195","author":"Gu\u00e9guen","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2026.104199_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2023.101705","article-title":"Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery","volume":"66","author":"C\u00e1rdenas","year":"2023","journal-title":"Curr Opin Colloid In"},{"issue":"10","key":"10.1016\/j.xphs.2026.104199_bib0018","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.tibtech.2022.03.012","article-title":"Quality by Design for enabling RNA platform production processes","volume":"40","author":"Daniel","year":"2022","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","article-title":"Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery","volume":"40","author":"Sun","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104199_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122874","article-title":"Impact of non-ionizable lipids and phase mixing methods on structural properties of lipid nanoparticle formulations","volume":"637","author":"Pratsinis","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104199_bib0021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2024.08.016","article-title":"The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA","volume":"374","author":"Barbieri","year":"2024","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0022","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.xphs.2022.12.026","article-title":"Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice","volume":"112","author":"Kawaguchi","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0023","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J Pharm Sci"},{"issue":"15","key":"10.1016\/j.xphs.2026.104199_bib0024","first-page":"E3351","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Arteta","year":"2018","journal-title":"P Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.xphs.2026.104199_bib0025","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1021\/acs.molpharmaceut.4c00826","article-title":"Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects","volume":"21","author":"Kafle","year":"2024","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0026","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14760584.2025.2596674","article-title":"Not so cold! Improving the thermostability of mRNA vaccines","volume":"24","author":"Haensler","year":"2025","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.xphs.2026.104199_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0028","article-title":"Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine","volume":"12","author":"Tong","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.xphs.2026.104199_bib0029","unstructured":"Draft Guideline on the quality aspects of mRNA vaccines European Medicines Agency EMA\/CHMP\/BWP\/82416\/2025 [updated 27 March 2025. Available from: https:\/\/www.ema.europa.eu\/en\/development-guideline-quality-aspects-mrna-vaccines-scientific-guideline."},{"key":"10.1016\/j.xphs.2026.104199_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jare.2021.09.003","article-title":"Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine","volume":"38","author":"da","year":"2022","journal-title":"J Adv Res"},{"key":"10.1016\/j.xphs.2026.104199_bib0031","author":"Dongsheng","year":"2021","journal-title":"Azo calixarene pharmaceutical adjuvant and use thereof"},{"issue":"10","key":"10.1016\/j.xphs.2026.104199_bib0032","article-title":"Calixarene-Guest Complexes: The Next Innovation in Delivery of Drugs and Biologics","volume":"7","author":"Muley","year":"2024","journal-title":"Adv Ther-Germany"},{"issue":"8","key":"10.1016\/j.xphs.2026.104199_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081250","article-title":"Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery","volume":"13","author":"Lebr\u00f3n","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41467-018-07751-4","article-title":"The synthesis and characterization of giant Calixarenes","volume":"10","author":"Guerineau","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104199_bib0035","unstructured":"Kallel H. LR, Boulanger E., Benini G., Flaba A., Sies A. Castillo J. Rabies mRNA Vaccine Case Study: Quality and Manufacturing of the IVT Performance using Ntensify(TM) Technology 2023 [Available from: https:\/\/quantoom.com\/resource\/rabies-mrna-vaccine-case-study\/."},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.xphs.2026.104199_bib0038","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.xphs.2026.104199_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.xphs.2026.104199_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124514","article-title":"Design and lyophilization of mRNA-encapsulating lipid nanoparticles","volume":"662","author":"Wang","year":"2024","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104199_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/biom9030090","article-title":"Calixarenes: Generalities and Their Role in Improving the Solubility, Biocompatibility, Stability, Bioavailability, Detection, and Transport of Biomolecules","volume":"9","author":"Espa\u00f1ol","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.xphs.2026.104199_bib0042","unstructured":"Organization WH. The immunological basis for immunization series: module 17: rabies. The immunological basis for immunization series: module 17: rabies2017."},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of Lipid Nanoparticles for RNA Delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.xphs.2026.104199_bib0044","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2026.104199_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<443::AID-JPS2>3.0.CO;2-W","article-title":"Chemical stability of nucleic acid-derived drugs","volume":"89","author":"Pogocki","year":"2000","journal-title":"J Pharm Sci"},{"issue":"23","key":"10.1016\/j.xphs.2026.104199_bib0046","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1021\/ja990592p","article-title":"Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2\u2032-hydroxyl","volume":"121","author":"Li","year":"1999","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0047","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0048","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s42003-024-06235-0","article-title":"Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids","volume":"7","author":"Hashiba","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.xphs.2026.104199_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114235","article-title":"Analytical techniques for the characterization of nanoparticles for mRNA delivery","volume":"198","author":"Nogueira","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2026.104199_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"issue":"9-10","key":"10.1016\/j.xphs.2026.104199_bib0051","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/elps.202100244","article-title":"Determination of lipid content and stability in lipid nanoparticles using ultra high-performance liquid chromatography in combination with a Corona Charged Aerosol Detector","volume":"43","author":"Kinsey","year":"2022","journal-title":"Electrophoresis"},{"issue":"7","key":"10.1016\/j.xphs.2026.104199_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071029","article-title":"Pre-Drawn Syringes of Comirnaty for an Efficient COVID-19 Mass Vaccination: Demonstration of Stability","volume":"13","author":"Selmin","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.xphs.2026.104199_bib0053","article-title":"Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty (Pfizer) and Spikevax (Moderna): A Comparative Study of the Particulate","volume":"11","author":"Hermosilla","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.xphs.2026.104199_bib0054","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11095-024-03671-9","article-title":"Characterization of mRNA Lipid Nanoparticles by Electron Density Mapping Reconstruction: X-ray Scattering with Density from Solution Scattering (DENSS) Algorithm","volume":"41","author":"Dao","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104199_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122243","article-title":"Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications","volume":"301","author":"Goldman","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2026.104199_bib0056","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.xphs.2026.104199_bib0057","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jconrel.2024.11.007","article-title":"Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity","volume":"376","author":"Wu","year":"2024","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0058","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104199_bib0059","unstructured":"Padilla MS, Shepherd SJ, Hanna AR, Kurnik M, Zhang X, Chen M, et al. Solution biophysics identifies lipid nanoparticle non-sphericity, polydispersity, and dependence on internal ordering for efficacious mRNA delivery. bioRxiv. 2025."},{"issue":"24","key":"10.1016\/j.xphs.2026.104199_bib0060","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.xphs.2026.104199_bib0062","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307798120","article-title":"Recent advances in nanoparticulate RNA delivery systems","volume":"121","author":"Witten","year":"2024","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1016\/j.xphs.2026.104199_bib0063","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/acs.molpharmaceut.4c00925","article-title":"Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics","volume":"22","author":"Yuan","year":"2025","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104199_bib0064","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11262-024-02102-6","article-title":"Advances in the study of LNPs for mRNA delivery and clinical applications","volume":"60","author":"Wang","year":"2024","journal-title":"Virus Genes"},{"issue":"4","key":"10.1016\/j.xphs.2026.104199_bib0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","article-title":"Strategies to reduce the risks of mRNA drug and vaccine toxicity","volume":"23","author":"Bitounis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.xphs.2026.104199_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13060500","article-title":"Brief Insights into mRNA Vaccines: Their Successful Production and Nanoformulation for Effective Response against COVID-19 and Their Potential Success for Influenza A and B","volume":"13","author":"Parveen","year":"2024","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.xphs.2026.104199_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12080873","article-title":"Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems","volume":"12","author":"Wu","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.xphs.2026.104199_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121570","article-title":"An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates","volume":"286","author":"Ripoll","year":"2022","journal-title":"Biomaterials"},{"issue":"24","key":"10.1016\/j.xphs.2026.104199_bib0069","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1039\/D4BM01070A","article-title":"Formulation of lipid nanoparticles containing ginsenoside Rg2 and protopanaxadiol for highly efficient delivery of mRNA","volume":"12","author":"Park","year":"2024","journal-title":"Biomater Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70680-4","article-title":"Impact of mixing and shaking on mRNA-LNP drug product quality characteristics","volume":"14","author":"Matthessen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104199_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114265","article-title":"Don't shake it! Mechanical stress testing of mRNA-lipid nanoparticles","volume":"198","author":"Ruppl","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2026.104199_bib0072","series-title":"Analytical Procedures for mRNA Vaccine Quality: Draft Guidelines","author":"Pharmacopeia","year":"2023"},{"key":"10.1016\/j.xphs.2026.104199_bib0073","first-page":"1745","article-title":"Characterisation and analysis of mRNA critical quality attributes using liquid chromatography based methods","author":"Webb","year":"2025","journal-title":"J Chromatogr A"},{"issue":"23","key":"10.1016\/j.xphs.2026.104199_bib0074","doi-asserted-by":"crossref","first-page":"21206","DOI":"10.1021\/acsnano.4c18274","article-title":"Structure and Morphology of Lipid Nanoparticles for Nucleic Acid Drug Delivery: A Review","volume":"19","author":"Udepurkar","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2026.104199_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116352","article-title":"Comparison of capillary electrophoresis-based methods for the analytical characterization of purity and stability of in vitro transcribed mRNA","volume":"249","author":"Mantri","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2026.104199_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2024.115040","article-title":"Validation of an HPLC-CAD method for measuring the lipid content of novel LNP-encapsulated COVID-19 mRNA vaccines","volume":"330","author":"Yang","year":"2024","journal-title":"J Virol Methods"},{"issue":"7","key":"10.1016\/j.xphs.2026.104199_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30071629","article-title":"Current Analytical Strategies for mRNA-Based Therapeutics","volume":"30","author":"Camperi","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2026.104199_bib0078","volume":"13","author":"Gau","year":"2023"},{"issue":"14","key":"10.1016\/j.xphs.2026.104199_bib0079","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/acs.analchem.4c00031","article-title":"Analytical Characterization of Heterogeneities in mRNA-Lipid Nanoparticles Using Sucrose Density Gradient Ultracentrifugation","volume":"96","author":"Vaidya","year":"2024","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0080","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104199_bib0081","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2024.01.037","article-title":"Quality assessment of LNP-RNA therapeutics with orthogonal analytical techniques","volume":"367","author":"Parot","year":"2024","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0082","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-025-01181-2","article-title":"Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines","volume":"10","author":"Sanyal","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0083","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0084","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020430","article-title":"Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain","volume":"14","author":"Kis","year":"2022","journal-title":"Pharmaceutics"},{"issue":"20","key":"10.1016\/j.xphs.2026.104199_bib0085","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and Lipid Derivatives for RNA Delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem Rev"},{"issue":"5","key":"10.1016\/j.xphs.2026.104199_bib0086","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1208\/s12249-022-02282-0","article-title":"Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation","volume":"23","author":"Musakhanian","year":"2022","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.xphs.2026.104199_bib0087","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0088","first-page":"358","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhao","year":"2020","journal-title":"Bioact Mater"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104199_bib0089","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0005-2736(00)00251-0","article-title":"Stabilization of lipid\/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis","volume":"1468","author":"Allison","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2026.104199_bib0090","article-title":"Recent advances in drying and development of solid formulations for stable mRNA and siRNA lipid nanoparticles","author":"Arte","year":"2024","journal-title":"J Pharm Sci"},{"issue":"20","key":"10.1016\/j.xphs.2026.104199_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012487","article-title":"The Role of Cryoprotective Agents in Liposome Stabilization and Preservation","volume":"23","author":"Boafo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104199_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.06.007","article-title":"Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement","volume":"27","author":"Grau","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.xphs.2026.104199_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/bmjos-2021-100203","article-title":"Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres","volume":"5","author":"Kudsiova","year":"2021","journal-title":"BMJ Open Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104199_bib0094","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2010.10.025","article-title":"Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles","volume":"403","author":"Crawford","year":"2011","journal-title":"Int J Pharm"},{"issue":"31","key":"10.1016\/j.xphs.2026.104199_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303370","article-title":"Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency","volume":"35","author":"Cheng","year":"2023","journal-title":"Adv Mater"},{"issue":"2","key":"10.1016\/j.xphs.2026.104199_bib0096","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/17425247.2023.2162876","article-title":"Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out","volume":"20","author":"De","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104199_bib0097","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2024.07.046","article-title":"A perspective on bleb and empty LNP structures","volume":"373","author":"Simonsen","year":"2024","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2026.104199_bib0098","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/acs.molpharmaceut.4c01437","article-title":"Molecular Insight into Lipid Nanoparticle Assembly from NMR Spectroscopy and Molecular Dynamics Simulation","volume":"22","author":"Li","year":"2025","journal-title":"Mol Pharmaceut."},{"key":"10.1016\/j.xphs.2026.104199_bib0099","series-title":"Deciphering the Role of PEGylation on the Lipid Nanoparticle-Mediated mRNA Delivery to the Liver","author":"Gao","year":"2025"},{"issue":"19","key":"10.1016\/j.xphs.2026.104199_bib0100","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1016\/j.biomaterials.2012.03.038","article-title":"Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid","volume":"33","author":"Chan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2026.104199_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.882363","article-title":"Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines","volume":"10","author":"Padin-Gonzalez","year":"2022","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:55:10Z","timestamp":1786218910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022354926000481"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104199","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104199"}}